


Cloud Pharmaceuticals Selected Finalist in U.S.-China Health Summit

After competing with 13 other semifinalist start-ups at Harvard, Cloud was selected to travel and present in Chengdu, Sichuan Oct. 12-14 2018

DURHAM, NC, UNITED STATES, October 4, 2018 /EINPresswire.com/ -- Cloud Pharmaceuticals has been selected as a finalist in the U.S.-China Health Summit competition and was awarded travel and a presentation spot at the finals in Chengdu, Sichuan, China October 12-14, 2018.

As a key forum for promoting exchange in the health field, the Summit has been alternately hosted by U.S. and China, receiving continuous support from The National Health and Family Planning Commission of China and the

U.S. Department of Health and Human Services.



Don Van Dyke, Cloud's Chief Operating Officer, made the winning presentation at Harvard



It was a great experience to be selected from a group of such fine early-stage companies. We appreciated showing how Cloud's technology allows companies to leap forward in the design of new drugs.""

Don Van Dyke

University, School of Public Health, on September 8th. He said, "It was a great experience to be selected from a group of such fine early-stage companies. We appreciated the chance to show how Cloud's technology allows pharmaceutical companies to leap forward in the process of early design of novel therapies." The award sends Van Dyke to Chengdu to represent the company in the finals.

Cloud Pharmaceuticals is a leader in the burgeoning field of Artificial Intelligence based drug discovery. The company partners, designs, develops, and licenses novel drug compounds for a wide range of medical indications to the pharmaceutical, biotechnology and medical research

markets.

The company launched in 2011 with a technology license from Duke University, and has since expanded through early stage funding arrangements from Microsoft, the National Science Foundation, and the University of Florida via its Gatorade royalty fund, and has more recently established a long-term collaboration with Glaxosmithkline ("GSK").

Since its inauguration in 2011 at Harvard University, the U.S.-China Health Summit (the Summit) has been dedicated to advancing global health by promoting exchange of knowledge, ideas and experiences among current and future health sector leaders from China, the U.S. and other

countries. The annual Summit has been held alternately in the U.S. and China which gathers together hundreds of leaders from academia, governmental and non-governmental organizations as well as industry to discuss important challenges and opportunities in health sector reforms and development.

Don VAN DYKE Cloud Pharmaceuticals 9193452838 email us here Visit us on social media: Twitter LinkedIn



This press release can be viewed online at: http://www.einpresswire.com

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases. © 1995-2018 IPD Group, Inc. All Right Reserved.